458 related articles for article (PubMed ID: 28595996)
1. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
Smith SH; Jayawickreme C; Rickard DJ; Nicodeme E; Bui T; Simmons C; Coquery CM; Neil J; Pryor WM; Mayhew D; Rajpal DK; Creech K; Furst S; Lee J; Wu D; Rastinejad F; Willson TM; Viviani F; Morris DC; Moore JT; Cote-Sierra J
J Invest Dermatol; 2017 Oct; 137(10):2110-2119. PubMed ID: 28595996
[TBL] [Abstract][Full Text] [Related]
2. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
Bissonnette R; Stein Gold L; Rubenstein DS; Tallman AM; Armstrong A
J Am Acad Dermatol; 2021 Apr; 84(4):1059-1067. PubMed ID: 33157177
[TBL] [Abstract][Full Text] [Related]
3. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.
Vu YH; Hashimoto-Hachiya A; Takemura M; Yumine A; Mitamura Y; Nakahara T; Furue M; Tsuji G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321923
[TBL] [Abstract][Full Text] [Related]
4. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
Bobonich M; Gorelick J; Aldredge L; Bruno MJ; DiRuggiero D; Martin G; Tallman AM; Gold LS
J Drugs Dermatol; 2023 Aug; 22(8):779-784. PubMed ID: 37556512
[TBL] [Abstract][Full Text] [Related]
5. Natural Compounds Tapinarof and
Tsuji G; Hashimoto-Hachiya A; Matsuda-Taniguchi T; Takai-Yumine A; Takemura M; Yan X; Furue M; Nakahara T
Front Immunol; 2022; 13():745997. PubMed ID: 35663970
[TBL] [Abstract][Full Text] [Related]
6. Tapinarof to treat psoriasis.
Rodríguez Baisi K; Tollefson M
Drugs Today (Barc); 2020 Aug; 56(8):515-530. PubMed ID: 33025947
[TBL] [Abstract][Full Text] [Related]
7. Diosmin restores the skin barrier by targeting the aryl hydrocarbon receptor in atopic dermatitis.
Lee J; Song KM; Jung CH
Phytomedicine; 2021 Jan; 81():153418. PubMed ID: 33302042
[TBL] [Abstract][Full Text] [Related]
8. Tapinarof Cream 1%: First Approval.
Keam SJ
Drugs; 2022 Jul; 82(11):1221-1228. PubMed ID: 35939180
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
Eichenfield LF; Silverberg JI; Hebert AA; Chovatiya R; Brown PM; McHale KA; Rubenstein DS; Tallman AM
J Drugs Dermatol; 2024 Feb; 23(2):23-28. PubMed ID: 38306128
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
[TBL] [Abstract][Full Text] [Related]
11. Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
Bissonnette R; Vasist LS; Bullman JN; Collingwood T; Chen G; Maeda-Chubachi T
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):524-531. PubMed ID: 29389078
[TBL] [Abstract][Full Text] [Related]
12. The opposite effect of tapinarof between IMQ and IL-23 induced psoriasis mouse models.
Zhu X; Han R; Tian X; Hochgerner M; Li H; Wang J; Xia J
Exp Dermatol; 2024 Jan; 33(1):e14862. PubMed ID: 37350230
[TBL] [Abstract][Full Text] [Related]
13. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
[TBL] [Abstract][Full Text] [Related]
14. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
[TBL] [Abstract][Full Text] [Related]
15. Role of Aryl Hydrocarbon Receptor Activation and Autophagy in Psoriasis-Related Inflammation.
Kim HR; Kang SY; Kim HO; Park CW; Chung BY
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32235789
[TBL] [Abstract][Full Text] [Related]
16. Anti-Inflammatory and Pro-Differentiating Properties of the Aryl Hydrocarbon Receptor Ligands NPD-0614-13 and NPD-0614-24: Potential Therapeutic Benefits in Psoriasis.
Cardinali G; Flori E; Mastrofrancesco A; Mosca S; Ottaviani M; Dell'Anna ML; Truglio M; Vento A; Zaccarini M; Zouboulis CC; Picardo M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299118
[TBL] [Abstract][Full Text] [Related]
17. Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.
Furue M; Hashimoto-Hachiya A; Tsuji G
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683543
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.
Furue M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751111
[TBL] [Abstract][Full Text] [Related]
20. [The aryl hydrocarbon receptor as the target structure for new drugs in psoriasis and atopic dermatitis].
Merk HF
Hautarzt; 2019 Dec; 70(12):942-947. PubMed ID: 31728551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]